Physician profile
Alex J Schaffer
NPI 1538476171
$2,442.52
in general payments reported to CMS, 2019-2025
21 companies · $533 in 2025
The $533 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $52.58 · 2021: $26.18 · 2022: $528 · 2023: $512 · 2024: $526 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $486.37 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $283.90 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $227.71 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $224.49 | 2022 | |
| Alcon Vision LLC | $193.98 | 2019-2025 | Tryptyr, Simbrinza, Hydrus Microstent |
| Harrow Eye, LLC | $184.36 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $136.69 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $108.02 | 2022-2025 | Oxervate |
| Shire North American Group INC | $74.46 | 2019 | |
| Kala Pharmaceuticals, INC. | $74.27 | 2019-2022 | |
| Biotissue Holdings INC. | $65.07 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $62.80 | 2024 | Purified Cortrophin Gel |
| Sight Sciences, INC. | $57.86 | 2023 | Tearcare System |
| Eyevance Pharmaceuticals LLC | $55.14 | 2019-2021 | |
| Abbvie INC. | $46.91 | 2023-2024 | Alphagan P, Vuity, Lumigan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.22 | 2019 | |
| Horizon Therapeutics Plc | $42.13 | 2020-2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $26.86 | 2025 | Syfovre |
| Amgen INC. | $17.49 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $17.25 | 2019 | |
| Omeros Corporation | $14.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.